Financial Performance - Ginkgo's Q3 2025 total revenue was $39 million, a decrease of 56% year-over-year compared to $89 million in Q3 2024[34] - Cell Engineering revenue in Q3 2025 was $29 million, a 61% decrease compared to $75 million in Q3 2024, which includes $45 million of non-cash deferred revenue from Motif[23, 34] - Biosecurity revenue in Q3 2025 was $9 million, a 32% decrease compared to $14 million in Q3 2024[34] - Total Adjusted EBITDA for Q3 2025 was $(56) million, compared to $(20) million in Q3 2024[34] - Ginkgo reaffirms its full year 2025 total revenue guidance of $167-187 million[43] - Ginkgo's cash, cash equivalents, and marketable securities remain strong at $462 million as of Q3 2025[17] - Quarterly cash burn continues to improve, with a 73% decrease from the prior quarter[14] Strategic Focus - Ginkgo is expanding its business model into life science tools and services[54, 96] - Ginkgo believes AI models will impact biotechnology in two ways and is well-positioned to provide tools in both[48, 51, 93, 115] - Ginkgo continues to offer research solutions on top of its in-house robotics, winning new deals in Agriculture and with the US Government[49, 52, 94, 116] - Ginkgo is expanding its frontier autonomous lab in Boston as a showcase[50, 53, 95, 117, 118]

Financial Performance & Targets - Ginkgo achieved its target of $250 million in annualized run-rate cost savings from Q1 2024 to Q2 2025[13, 50] - Ginkgo's Q2 2025 Cell Engineering revenue was $39 million, an 8% increase year-over-year[34] - Biosecurity revenue for Q2 2025 was $10 million, a 48% decrease year-over-year[34] - The company reaffirms its total revenue guidance for FY2025, projecting $167-$187 million, including $117-137 million from Cell Engineering and $40+ million from Biosecurity[37, 52] - Ginkgo aims to reach Adjusted EBITDA breakeven by the end of 2026[11, 46, 53] - Ginkgo had $474 million in cash, cash equivalents, and marketable securities with no bank debt[15, 16] Strategic Initiatives - Ginkgo is expanding from its Solutions business into tools, launching its first direct-to-scientist product: a cell-free protein synthesis system[11, 43, 63] - Ginkgo's Automation and Datapoints are establishing themselves as critical tools in AI-enabled science[43, 143] - Ginkgo has sampled flights originating from 128 countries, representing 65% of nations globally[33]